Sunday, May 18, 2014

Foundation Medicine and Collaborators to Present New Clinical Data on FoundationOne® and FoundationOne Heme at the 2014 ASCO Annual Meeting








Date & Time: Saturday, May 31, 2014 from 8:00 a.m. to 11:45 a.m. CT
Title: Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy 
Presenter: Juliann Chmielecki, Ph.D. 

Date & Time: Saturday, May 31, 2014 from 1:15 p.m. to 5:00 p.m. CT
Title: BATTLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) 
Presenter: Vassiliki Papadimitrakopoulou, M.D.
Collaborator: The University of Texas MD Anderson Cancer Center 

Date & Time: Saturday, May 31, 2014 from 1:15 pm. to 5:00 p.m. CT
Title: Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma
Presenter: Siraj M. Ali, M.D., Ph.D. 

Date & Time: Saturday, May 31, 2014 from 1:15 p.m. to 5:00 p.m. CT
Title: Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in advanced solid tumors 
Presenter: Fadi S. Braiteh, M.D.
Collaborator: Comprehensive Cancer Centers of Nevada 

Date & Time: Saturday, May 31, 2014 from 1:15 p.m. to 5:00 p.m. CT
Title: Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations 
(GA) and new routes to targeted therapies
Presenter: Jeffrey S. Ross, M.D. 

Date & Time: Sunday, June 1, 2014 from 8:00 a.m. to 11:45 a.m. CT
Title: PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the Phase I clinic at MD Anderson: 
Prevalence and association with response
Presenter: Jennifer J. Wheler, M.D.
Collaborator: The University of Texas MD Anderson Cancer Center 

Date & Time: Monday, June 2, 2014 from 8:00 a.m. to 11:45 a.m. CT
Title: Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable 
genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience
Presenter: Matthew J. Hawryluk, Ph.D. 

Date & Time: Monday, June 2, 2014 from 8:00 a.m. to 11:00 a.m. CT
Title: Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent 
SND1-BRAF fusion 
Presenter: Juliann Chmielecki, Ph.D. 

Date & Time: Monday, June 2, 2014 from 8:00 a.m. to 11:45 a.m. CT
Title: Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 
(HER2)-amplified residual disease following preoperative anti-HER2 therapy 
Presenter: Frankie Ann Holmes, M.D.
Collaborator: Texas Oncology 

Date & Time: Monday, June 2, 2014 from 8:00 a.m. to 11:45 a.m. CT
Title: Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to 
capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes
Presenter: Joyce O'Shaughnessy, M.D.
Collaborator: Texas Oncology-Baylor Charles A. Sammons Cancer Center 

Date & TimeMonday, June 2, 2014 from 8:00 a.m. to 11:00 a.m. CT
Title: Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).
Presenter: Jonathan Ledermann,
Collaborator: AstraZeneca 

Date & TimeMonday, June 2, 2014 from 1:15 p.m. to 4:15 p.m. CT
Title: Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel 
Session: Poster Highlights Session
Presenter: Noa Ben-Baruch, M.D. 
Collaborator: Teva Pharmaceuticals 

Date & TimeMonday, June 2, 2014 from 1:15 p.m. to 5:00 p.m. CT
Title: Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin 
(AMVAC) in muscle-invasive bladder cancer (MIBC) 
Presenter: Elizabeth R. Plimack, M.D., M.S.
Collaborator: Fox Chase Cancer Center 

Date & Time: Monday, June 2, 2014 from 2:03 p.m. to 2:15 p.m. CT
Title: Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications 
Session: Clinical Science Symposium
Presenter: Vinod Ravi, M.D.
Collaborator: The University of Texas MD Anderson Cancer Center 

Date & Time: Monday, June 2, 2014 from 5:24 p.m. to 5:36 p.m. CT
Title: Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations
Session: Oral Abstract Session
Presenter: Brandon Hayes-Lattin, M.D. 

Date & Time: Tuesday, June 3, 2014 from 8:00 a.m. to 11:00 a.m. CT
Title: Rictor amplification to define a novel and unique subset of lung cancer patients
Presenter: Haiying Cheng, M.D., Ph.D.
Collaborator: Columbia University Medical Center 

Date & Time: Tuesday, June 3, 2014 from 8:00 a.m. to 11:00 a.m. CT
Title: Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in "pan-negative" lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history
Presenter: Alexander E. Drilon, M.D.
Collaborator: Memorial Sloan-Kettering Cancer Center 

We organized this piece to be more helpful than the one on the official ASCO website,
POTC-
http://psychologyofthecall.blogspot.com

No comments: